A PROSPECTIVE RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED CROSSOVER STUDY OF FLUOXETINE EFFICACY IN THE PROPHYLAXIS OF CHRONIC DAILY HEADACHE IN CHILDREN AND ADOLESCENTS

José Luiz Dias Gherpelli¹, Sandro Blasi Esposito¹

ABSTRACT - Thirty-two children (21 female and 11 male), between 7 and 14 years old, with chronic daily headache (CDH) were consecutively included in a prospective, randomized, double blind, placebo controlled crossover study. The patients were divided in group I (fluoxetine vs. placebo), with 17 patients and group II (placebo vs. fluoxetine), with 15 patients. After one month of baseline headache frequency recording, the patients received fluoxetine in dosages from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months treatment period. Results showed a significant decrease in headache frequency in the study period [78% reduction in group I (p<0.025), and 45% reduction in group II (p=0.025)]. Gastrointestinal adverse effects were observed in nine patients (29%) that received fluoxetine, compared with 3 (10%), with placebo. We conclude that fluoxetine efficacy is not higher than placebo in the prophylaxis of CDH in children and adolescents.

KEY WORDS: headache, chronic daily headache, children and adolescents, migraine, fluoxetine.

Child and Adolescence Headache Clinic, Department of Neurology, Clinics Hospital, University of São Paulo Medical School, São Paulo SP, Brazil; 1MD, PhD Pediatric Neurologist. Financial support: Sigma-Pharma Company.

Received 8 December 2004, received in final form 3 March 2005. Accepted 15 April 2005.

The term chronic daily headache (CDH) is used to refer to headaches that occur ≥15 days/month. Silberstein et al.¹ classified CDH into two types, each with or without medication overuse. CDH is divided into primary and secondary varieties. Primary CDH can be subclassified into disorders of short (<4 hours) and long (>4 hours) duration. Primary CDH of long duration include chronic tension-type headache, chronic migraine (previously called transformed migraine), new daily persistent headache and hemicrania continua¹. In adults, 4-5% of the general population have CDH². There are few studies addressing CDH in children. Almost 50% of children with frequent headaches are left without diagnosis, when the adult diagnostic criteria are used in this age group, what lead to the proposal of a new CDH category for children called comorbid or mixed pattern, that includes cases in which migrainous and tension-type headache patterns exist independently of each other, without...
any transformation. Abu-Arfeh studied 115 children and adolescents with almost daily headache and found that 63.5% had chronic tension-type headaches, while 30.4% had independent episodes of migrainous and tension-type headaches, the comorbid type, and only 4.3% were classified as analgesic overuse headache. Among 40 children and adolescents with chronic daily headaches over the last 6 months, we found 65% of transformed migraine, 17.5% of the mixed pattern and 17.5% of chronic tension-type headache.

The treatment of primary CDH is complicated by analgesic overuse, comorbid psychiatric disorders, low frustration tolerance and emotional problems in adults. There are few well-designed studies in the literature, although the antidepressant amitriptyline and several drugs used for migraine prophylaxis seem to be useful.

Fluoxetine, a selective serotonin-reuptake inhibitor antidepressant, is a phenylpropylamine-derivative. The drug differs structurally from other selective serotonin-reuptake inhibitors (e.g., citalopram, paroxetine, sertraline) and also differs structurally and pharmacologically from other currently available antidepressant agents (e.g., tricyclic antidepressants, monoamine oxidase inhibitors). Fluoxetine is widely used as antidepressive in adults, as well as in children and adolescents.

Efficacy of fluoxetine for migraine prophylaxis was reported by some authors, while others were unable to observe such effect. A double-blind placebo-controlled study showed fluoxetine to be useful in the treatment of chronic daily headache. Others, using it in association with amitriptyline, could not observe this effect.

The objective of this study was to test the efficacy of fluoxetine prophylaxis in a group of children and adolescents with primary CDH through a prospective, randomized, double blind, placebo-controlled, crossover study.

METHOD

From January 1999 to April 2002, 40 children (30 female and 10 male), between 7 and 14 years old, with a diagnosis of primary CDH according to the Silberstein criteria were seen in the outpatient headache clinic. Thirty-two patients (21 female and 11 male) agreed to participate in our study. The ethics commission of our institution previously approved the study protocol and a signed informed consent was obtained from the parents.

All patients had a normal neurological examination and were instructed to fill out questionnaires of self-evaluation for depression, anxiety and life quality.

None of the patients used common analgesics more than 10 days/month during the study period. Patients were allowed to take the analgesics that were currently used before the beginning of the study. No patient used analgesics containing narcotics. The authors did not change the type of analgesic that was being used before the study period. Only the dosage was adjusted according to the patient’s age and weight. The most commonly used were paracetamol and dipirone, with or without caffeine, isometheptene, and ergotamine. Analgesics for acute pain relief were allowed during the wash-out period as well.

Environmental factors were not controlled during the study period, but no specific advices were given concerning daily activities, sleep or food habits, to the patients or their families.

All patients had a primary headache with a headache frequency of ≥15 days/month, for a period of at least 6 months before the initial evaluation. CDH diagnosis was based on Silberstein et al. and Gladstein and Holden modified criteria for children. Chronic daily migraine (transformed migraine) included meeting International Headache Society (IHS) criteria for migraine in the past, daily or almost daily (>15 days/month) headache for more than 1 month, average headache duration of 4 hours, and a history of increased headache frequency with decreased migraine symptoms over the last 3 months. Criteria for chronic tension-type headache included headache frequency of more than 15 days per month, with a duration of pain lasting more than 4 hours per day for at least 6 months. Also, patients should have pressing, bilateral pain with mild to moderate severity that is not aggravated by physical activity. There should be a history of episodic tension-type headache in the past, with an evolution to daily headaches in the past 3 months, and an absence of autonomic symptoms. Mixed (or comorbid) pattern included patients with a high frequency of migraine headache symptomatology intermixed with tension type headache.

The patients were randomly assigned to two groups: group I received fluoxetine and later placebo, and group II that started with placebo and received fluoxetine in the last study period. After one month of baseline headache frequency recording, the patients received fluoxetine (or placebo) in dosages that varied from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months period of drug treatment (Fig 1).

The drug were delivered in solution flasks of 50 ml (10 mg/ml of fluoxetine) labeled with the letters A or B. The initial fluoxetine dosage was 0.25 mg/kg/day, administered once a day, in the morning, and was eventually increased up to a maximum dosage of 0.5 mg/kg/day, or 20 mg/day, according to the therapeutic response (reduction <50% of headache frequency).

Monthly visits were scheduled where headache frequency and adverse effects were recorded through a...
headache diary. The presence and intensity of adverse
effects lead to dosage decrease, or drug withdrawal.
Drug compliance was monitored through the flasks
residual volume, after each visit.

The following tests were used for statistical analy-
sis: 1. Friedman test for rank variance analysis, with the
objective of comparing headache frequency, for each
patient, in each visit, and, when significant, was comple-
mented by the test of multiple comparisons. 2. Wilcoxon
test comparing the baseline and final headache fre-
quency for each patient. Significance value was p<.05. The
test power was established at 80%, for a decrease in
headache frequency of ±50%.

RESULTS
Group I included 17 patients (11 female, 6 male)
and group II, 15 patients (10 female, 5 male). Of
the 17 patients initially included in group I, 7 com-
pleted the whole study, 4 completed only the first
three months period, and 6 abandoned the study
for several reasons (2 for lack of response, 3, due
to adverse effects, and one moved to another state). In group II, of the 15 initially randomized pa-
tients, 10 completed the study, 2 completed only
the first three months period, and 3 dropped out
(one due to adverse effects and 2 for ignored rea-
sons).

Seventeen patients completed the whole study
period, 7 in group I, and 10, in group II, and data
on these patients were used for statistical analy-
sis purposes. The sex distribution, mean age, ini-
tial and final headache frequency, and CDH diag-
nosis are shown in the Table. Seventy percent of
the patients were classified as chronic daily migra-
nie (transformed migraine), 23.5%, as mixed (co-
morbid) pattern, and only one patient, as chronic
tension-type headache.

There was no statistically significant difference
between the children that completed the study
and the dropouts concerning age, sex, headache
frequency, analgesic intake, headache diagnosis,
and questionnaires ranks of anxiety, depression
and life quality.

Six of the seventeen patients that completed
the study (35.3%) had scores that suggested a de-
pressive trait, two patients of group I, and 4, of
group II. Four (23.5%) patients had scores that re-
vealed a high anxiety status, one of group I, and
3, of group II. Four patients (23.5%) had low scores
in the quality of life questionnaire, one of group
I, and 3, of group II.

Headache frequency during the study period is
shown in Fig 2.

The mean monthly headache frequency of
group I (fluoxetine) decreased from 18.8 to 5.7
(70% reduction), and of group II (placebo), from
23.9 to 14.2 (40% reduction), during the first three
months period. Statistical analysis using Friedman
variance test for ranks showed a significant decrea-
se in headache frequency in both group I (p<0.02)
and group II (p<0.02) after the first three months
period (Fig 3).

Table. General data of the groups that completed the study.

<table>
<thead>
<tr>
<th>Group</th>
<th>Sex</th>
<th>Age (mean)</th>
<th>Initial / Final mean headache frequency</th>
<th>CDH diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>6 F / 1 M</td>
<td>9.7 y (8 – 12)</td>
<td>18.5 / 4.1</td>
<td>6 CDM; 1 MP</td>
</tr>
<tr>
<td>II</td>
<td>6 F / 4 M</td>
<td>11.4 y (7 – 14)</td>
<td>23.9 / 13.1</td>
<td>6 CDM; 3 MP; 1 CTTH</td>
</tr>
</tbody>
</table>

CDH, chronic daily headache; CDM, chronic daily migraine; MP, mixed (or comorbid) pattern; CTTH, chronic tension-
type headache; F, female; M, male.
In the last three months period the mean monthly headache frequency decreased from 7.1 to 4.1 (42% reduction), in group I, while in group II, the frequency decreased from 18.7 to 13.1 (30% reduction), as shown in Fig 2. In the second study period, we only observed a significant decrease of the monthly headache frequency in patients receiving placebo (p<0.001). There was no significant decrease in headache frequency in patients taking fluoxetine (Fig 2).

We observed that both groups had a significant decrease of headache frequency when we compared the initial baseline frequency with that recorded at the end of the seven months of the study period. Patients in group I had a decrease of mean monthly headache frequency from 18.8 to 4.1 (p<0.025), a 78% reduction, and patients in group II, from 23.9 to 13.1 (p=0.025), a 45% reduction, as shown in Fig 2.

Thirty-one patients received at least one month of fluoxetine and 29, of placebo. Nine patients (29%) referred adverse effects possibly related to fluoxetine, and four had the drug withdrawn and could not complete the study. Three patients (10%) receiving placebo complained of adverse effects. Gastrointestinal system complaints (nausea, diarrhea) were the only adverse effects recorded.

**DISCUSSION**

Considering the whole study period (seven months), our study showed a statistically significant decrease in headache frequency that was independent of the drug. The reduction was statistically significant for patients taking either flu-
oxetine, or placebo, in the first three months, and only for patients on placebo, in the last three months. The overall reduction, considering the 17 patients that completed the whole study period, was of 60% of the initial headache frequency. These results indicate that CDH in children and adolescents has a natural history that is more benign, in terms of spontaneous decrease of headache frequency, from that observed in adults.

The placebo effect observed in our study was of 40% reduction in headache frequency in both parts of the study, a higher rate than that observed by others in adults, around 25-30%\textsuperscript{10,11}.

Although several patients exhibited psychological traits suggestive of depression and anxiety, we could not establish their role in headache frequency variation due to the small sample size.

The low number of patients that completed the study could be a confounding factor in the interpretation of the results. A high drop out rate with studies using this methodology and the long treatment period is a problem frequently observed. We agree that a higher number of patients would be desirable. Notwithstanding, when performing studies looking for higher than 40% effectiveness in symptom’s reduction, together with long study periods, the number of patients needed for valid statistical purposes is considerably reduced, and our data is within the values required\textsuperscript{13}. We tried to design the study according to recent recommendation of the IHS for the study of drug efficacy in headache patients\textsuperscript{14}, and we could not find any other study in the literature that used this strict methodology in children and adolescents.

We conclude that fluoxetine is not superior to placebo in the treatment of CDH in children and adolescents. CDH in this age group may have a different natural history from that observed in adults. The high rate of spontaneous reduction of headache frequency over several months observed in our study is a fact that should lead to other studies that address the basic mechanisms for CDH maintenance in children. This should be taken into account when studying CDH in this age group.

Acknowledgments – Appreciation is extended to Dr. Neil Ferreira Novo for statistical analysis.

REFERENCES